Literature DB >> 22232356

Topiramate effect in opsoclonus-myoclonus-ataxia syndrome.

Thiago Dias Fernandes1, Rodrigo Bazan, Luiz Eduardo Betting, Fernando Coronetti Gomes da Rocha.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22232356     DOI： 10.1001/archneurol.2011.717

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


× No keyword cloud information.
  4 in total

1.  Clinical and Immunological Features of Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies.

Authors:  Thaís Armangué; Lidia Sabater; Estefanía Torres-Vega; Eugenia Martínez-Hernández; Helena Ariño; Mar Petit-Pedrol; Jesús Planagumà; Luis Bataller; Josep Dalmau; Francesc Graus
Journal:  JAMA Neurol       Date:  2016-04       Impact factor: 18.302

2.  Delayed Opsoclonus-Myoclonus Syndrome After Ovarian Teratoma Resection.

Authors:  Andrea A Jones; Tychicus Chen
Journal:  J Neuroophthalmol       Date:  2021-08-17       Impact factor: 4.415

Review 3.  Physiology-Based Treatment of Myoclonus.

Authors:  Ashley B Pena; John N Caviness
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

4.  Case Report: Opsoclonus-Myoclonus Syndrome Associated With Contactin-Associated Protein-Like 2 and Acetylcholine Receptor Autoantibodies in the Setting of Non-Small Cell Lung Carcinoma.

Authors:  Christian S Rosenow; Sara Dawit; Luca P Farrugia; Katharine A Henry Ma; Akanksha Sharma; Andrew McKeon; Alyx B Porter; Marie F Grill
Journal:  Neurohospitalist       Date:  2021-05-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.